MCE products for research use only. We do not sell to patients.

(S)-(+)-Ibuprofen

MCE China：(S)-(+)-Ibuprofen

Brand：MedChemExpress (MCE)

Cat. No.HY-78131A

CAS：51146-56-6

Synonyms：Dexibuprofen

Purity：99.95%

Storage：Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year

Shipping：Room temperature in continental US; may vary elsewhere.

Description：(S)-(+)-Ibuprofen ((S)-Ibuprofen), a S(+)-enantiomer of Ibuprofen, is a potent COX-1 and COX-2 inhibitor with IC50s of 2.1 μM and 1.6 μM, respectively. (S)-(+)-Ibuprofen has analgesic, anti-inflammatory, anticancer and antipyretic effects.

In Vitro：(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 8 days) treatment reduces concentration dependently cell survival in both cell lines to a similar extent[2]. (S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 20-72 hours) treatment causes a G0/G1 phase block as well as apoptosis[2]. (S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 900 μM; 4-72 hours) treatment shows a down regulation of cyclin A and B and an increase of the cell cycle inhibitory protein p27Kip-1[2]. (S)-(+)-Ibuprofen inhibits COX activity, thromboxane formation, and platelet aggregation[1]. (S)-(+)-Ibuprofen inhibits the activation of NF-κB in response to T-cell stimulation with an IC50 of 61.7 μM[3].

In Vivo：(S)-(+)-Ibuprofen (15 mg/kg/day; intraperitoneal injection; five days a week; for 4 weeks) treatment inhibits tumor growth of HCA-7 and HCT-15 xenografts in the nude mice model[2].

IC50 & Target：COX-1 2.1 μM (IC50) COX-2 1.6 μM (IC50)

Hot selling product：Aducanumab  | 2-Aminoethyl diphenylborinate  | 4-Hydroperoxy cyclophosphamide  | Lapatinib  | ISO-1  | Metronidazole  | Dihydroartemisinin  | Artesunate  | Succinyl phosphonate (trisodium salt)  | SAFit11

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Evans AM, et al. Comparative pharmacology of S(+)-ibuprofen and (RS)-ibuprofen. Clin Rheumatol. 2001 Nov;20 Suppl 1:S9-14.  [Content Brief]

[2]. Astrid Janssen, et al. Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment. Eur J Pharmacol. 2006 Jul 1;540(1-3):24-33.  [Content Brief]

[3]. N Scheuren, et al. Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol. 1998 Feb;123(4):645-52.  [Content Brief]